GRX-917 PIPELINE

The primary clinical development focus is getting GRX-917 approved in generalized anxiety disorder by 2028, since GAD is a derisked indication with large unmet medical need.  Registration trials in GAD are planned to commence in 2025.

Additional large indications are supported by its mechanism of action and compelling preclincal efficacy data.